이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Karolinska Development 과거 수익 실적

과거 기준 확인 2/6

Karolinska Development의 수입은 연평균 -23.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 8.4%의 비율로 증가했습니다. 매출은 연평균 12.8%의 비율로 감소해 왔습니다. Karolinska Development의 자기자본이익률은 2.7%이고 순이익률은 1735%입니다.

주요 정보

-23.4%

수익 성장률

-35.0%

EPS 성장률

Pharmaceuticals 산업 성장	30.5%
매출 성장률	-12.8%
자기자본 수익률	2.7%
순이익	1,735.0%
다음 실적 업데이트	30 Aug 2024

최근 과거 실적 업데이트

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

May 04

Recent updates

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

May 04

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Aug 19

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Apr 27

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

Feb 08

수익 및 비용 분석

Karolinska Development 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:KDEV 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	2	34	23
31 Dec 23	2	5	22
30 Sep 23	2	17	22
30 Jun 23	2	-41	23
31 Mar 23	2	-87	23
31 Dec 22	2	-88	27
30 Sep 22	2	-118	27
30 Jun 22	2	-72	28
31 Mar 22	2	166	27
31 Dec 21	2	171	23
30 Sep 21	2	276	21
30 Jun 21	2	108	23
31 Mar 21	2	-106	24
31 Dec 20	3	-207	24
30 Sep 20	3	35	26
30 Jun 20	3	190	23
31 Mar 20	4	195	24
31 Dec 19	3	303	24
30 Sep 19	4	-11	21
30 Jun 19	4	8	20
31 Mar 19	3	32	16
31 Dec 18	3	31	16
30 Sep 18	3	48	20
30 Jun 18	3	238	22
31 Mar 18	3	185	24
31 Dec 17	2	180	25
30 Sep 17	5	125	23
30 Jun 17	5	-87	22
31 Mar 17	5	-142	20
31 Dec 16	5	-217	19
30 Sep 16	2	-315	24
30 Jun 16	2	-325	25
31 Mar 16	3	-904	29
31 Dec 15	3	-1,055	33
30 Sep 15	4	-980	41
30 Jun 15	5	-1,072	51
31 Mar 15	5	-608	53
31 Dec 14	5	-371	54
30 Sep 14	4	-424	47
30 Jun 14	5	-396	40
31 Mar 14	5	-169	40
31 Dec 13	5	-157	40
30 Sep 13	7	20	51

양질의 수익: KDEV 에는 SEK55.0M 큰 일회성 득실이 있습니다. SEK55.0M 은 지난 12개월 간의 재무 결과에 31st March, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: KDEV 는) 과거에 수익을 냈습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: KDEV 지난 5년 동안 수익을 창출하여 매년 -23.4% 수익을 올렸습니다.

성장 가속화: KDEV 지난해 흑자를 기록해 5년 평균과 비교하기 어려운 수익 성장률을 보이고 있습니다.

수익 대 산업: KDEV 작년에 수익을 올렸기 때문에 지난 해 수익 성장을 Pharmaceuticals 업계( 1.2% )와 비교하기가 어렵습니다.

Karolinska Development 과거 수익 실적

과거 기준 확인 2/6

주요 정보

최근 과거 실적 업데이트

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

First quarter 2024 earnings released

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

Recent updates

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Price target decreased to kr5.40

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Price target increased to kr7.90

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

New 90-day low: kr1.59

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: kr1.61

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

New 90-day low: kr1.80

Investor sentiment deteriorated over the past week

New 90-day low: kr2.17

New 90-day low: kr2.31

New 90-day low: kr2.60

New 90-day low: kr2.61